



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Medical benefit drug policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and therefore subject to change.

P&T Date: 04/10/2025

Jemperli (dostarlimab-gxly)

HCPCS: J9272

Policy:

Requests must be supported by submission of chart notes and patient specific documentation.

- A. Coverage of the requested drug is provided when all the following are met:
 - a. Treatment must follow the FDA approved indications or National Comprehensive Cancer Network (NCCN) guidelines when it is a Category 1 or 2A recommendation
 - i. Must be used with concomitant treatment according to FDA indication or NCCN Category 1 or 2A recommendation
 - b. Prescribed by or in consultation with an oncologist or hematologist
 - c. No prior failure of a programmed death receptor-1 (PD-1) inhibitor
 - d. Patient is not receiving therapy for a chronic condition, such as an autoimmune disease, that requires treatment with a systemic immunosuppressant
- B. Quantity Limitations, Authorization Period and Renewal Criteria
 - a. Quantity Limits: Align with FDA recommended dosing
 - b. Authorization Period: Aligns with FDA recommended or guideline supported treatment duration and provided for at least 60 days and up to 6 months at a time
 - c. Renewal Criteria: Treatment continued until unacceptable toxicity or disease progression occurs

***Note: Coverage and approval duration may differ for Medicare Part B members based on any applicable criteria outlined in Local Coverage Determinations (LCD) or National Coverage Determinations (NCD) as determined by Center for Medicare and Medicaid Services (CMS). See the CMS website at <http://www.cms.hhs.gov/>. Determination of coverage of Part B drugs is based on medically accepted indications which have supported citations included or approved for inclusion determined by CMS approved compendia.

Background Information:

- Jemperli is a programmed death receptor-1 (PD-1)–blocking antibody indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced
 - For the treatment of endometrial cancer in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent in adult patients with primary advanced or recurrent disease that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite instability-high (MSI-H)
 - For the treatment of adult patients with dMMR recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation
 - For the treatment of adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options
- The National Comprehensive Cancer Network (NCCN) guidelines category 1 and 2A recommendations are based on uniform NCCN consensus that the recommendations are appropriate. Treatment regimens have been studied and shown to be efficacious when administered as listed in the guidelines. Category 2B and 3 recommendations do not have a high level of evidence to support use and also do not have a uniform consensus from the NCCN panel that the recommendations are appropriate.
- There are no studies to support use of Jemperli following failure. NCCN treatment guidelines also do not recommend use of PD-L1 checkpoint inhibitors following a previous failure.
- Jemperli has not been studied in patients on chronic immunosuppressant therapy and therefore, should not be used in patients on chronic immunosuppressants.

References:

1. Jemperli [prescribing information]. Philadelphia, PA: GlaksoSmithKline LLC; August 2024.
2. Oaknin A, Tinker AV, Gilbert L, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol. 2020 Oct 1; 6 (11): 1 – 7.
3. National Comprehensive Cancer Network. Uterine neoplasms (Version 2.2025). 2025 Jan 31. Available at: https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf. Accessed on February 11, 2025.

Policy History												
#	Date	Change Description										
1.5	Effective Date: 04/10/2025	Annual review of criteria was performed, no changes were made										
1.4	Effective Date: 04/11/2024	Annual review of criteria was performed, no changes were made										
1.3	Effective Date: 04/06/2023	Updated approval length to allow for no less than a 60 day approval duration										
1.2	Effective Date: 06/09/2022	Updated approval length to allow for FDA recommended dosing or up to 6 months at a time										
1.1	Effective Date: 07/26/2021	UM medical management system update for all lines of business <table><tr><th>Line of Business</th><th>PA Required in Medical Management System (Yes/No)</th></tr><tr><td>BCBS</td><td>Yes</td></tr><tr><td>BCN</td><td>Yes</td></tr><tr><td>MAPPO</td><td>Yes</td></tr><tr><td>BCNA</td><td>Yes</td></tr></table>	Line of Business	PA Required in Medical Management System (Yes/No)	BCBS	Yes	BCN	Yes	MAPPO	Yes	BCNA	Yes
Line of Business	PA Required in Medical Management System (Yes/No)											
BCBS	Yes											
BCN	Yes											
MAPPO	Yes											
BCNA	Yes											
1.0	Effective Date: 06/10/2021	New Policy <table><tr><th>Line of Business</th><th>PA Required in Medical Management System (Yes/No)</th></tr><tr><td>BCBS</td><td>No</td></tr><tr><td>BCN</td><td>No</td></tr><tr><td>MAPPO</td><td>No</td></tr><tr><td>BCNA</td><td>No</td></tr></table>	Line of Business	PA Required in Medical Management System (Yes/No)	BCBS	No	BCN	No	MAPPO	No	BCNA	No
Line of Business	PA Required in Medical Management System (Yes/No)											
BCBS	No											
BCN	No											
MAPPO	No											
BCNA	No											

* The prescribing information for a drug is subject to change. To ensure you are reading the most current information it is advised that you reference the most updated prescribing information by visiting the drug or manufacturer website or <http://dailymed.nlm.nih.gov/dailymed/index.cfm>.